<DOC>
	<DOC>NCT02152384</DOC>
	<brief_summary>This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics. This study is expected to last up to 17 weeks.</brief_summary>
	<brief_title>A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have a stable (within 0.5 percent (%) from last measure) glycated hemoglobin (HbA1c) &lt;9.0% Have a stable (within 30%) basal insulin dose of 0.2 to 1.0 units per kilogram per day (U/kg/day) and a total daily insulin dose (basal + prandial/bolus) &lt;1.5 units per kilogram (U/kg) Have Cpeptide &lt;0.3 nanomoles per liter (nmol/L) Are able and willing to eat the protocol specified standard breakfast and other meals as required Have corrected QT interval (QTc) prolongation &gt;500 milliseconds (ms) or have any other abnormality in the 12 lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study Have an abnormal blood pressure as determined by the investigator Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus [T1DM]), hematological, or neurological disorders Have fasting triglycerides (TGs) &gt;400 milligrams per deciliter (mg/dL) (4.52 micromoles per liter [mmol/L]) Have used systemic corticosteroids within 4 weeks prior to randomization Currently receive insulin pump or insulin degludec Have poorly controlled diabetes or are known to have poor awareness of hypoglycemia Have history of gastroparesis or gastrointestinal malabsorption Require treatment with any drug other than insulin to treat diabetes Have a previous history of proliferative retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>